Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone.
Int J Pharm
; 568: 118466, 2019 Sep 10.
Article
em En
| MEDLINE
| ID: mdl-31254623
ABSTRACT
Some recent studies have shown that pirfenidone (PFD) has favorable results in the healing process of the cornea. However, PFD in solution exhibits short half-life after topical application, and in this context, a liquid crystal nanoparticle system containing PFD (PFD-LCNPs) was developed. The nanoparticles were characterized by transmission electron microscopy, atomic force microscopy, small angle X-ray diffraction and polarized light microscopy. The PFD-LCNPs had particle size and zeta potential of 247.3â¯nm and -33.60â¯mV (stores at 4⯰C), respectively, and 257.5â¯nm and -46.00â¯mV (stored at 25⯰C), respectively. The pH of the formulation was 6.9 and the encapsulation efficiency was 35.9%. The in vitro release profiles indicated that PFD sustained release from PFD-LCNPs for up to 12â¯h. In vitro study of ocular irritation (HET-CAM test) concluded that components of the formulation are well tolerated for ocular administration. Corneal re-epithelialization time after chemical burning was significantly reduced in rabbits treated with PFD-loaded LCNPs when compared to the group treated with a vehicle. In addition, the anti-inflammatory action of pirfenidone was observed by reducing myeloperoxidase activity (MPO) and inflammatory cells in the histology of the tissues of animals treated with PFD-LCNPs. These findings indicated that the PFD-LCNPs might have the potential for effective ocular drug delivery.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piridonas
/
Queimaduras Químicas
/
Queimaduras Oculares
/
Cristais Líquidos
/
Nanopartículas
/
Analgésicos
/
Anti-Inflamatórios
Limite:
Animals
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article